retina

OCT imaging yields better visualizationFuture increases in imaging speed will improve performance and functionality for OCT and OCT angiography (OCTA), said James Fujimoto, PhD.
5 observations about corticosteroids for DME treatmentFindings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.
How wide-field SS-OCT expands spectrum of normal peripheral retinaWide-field retinal imaging can be performed using a commercially available swept-source optical coherence tomography (SS-OCT) platform (DRI OCT Triton, Topcon) and only the internal fixation light for patient navigation provided detailed images of both normal and pathologic peripheral retinal findings.
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’A new hypersonic liquefaction vitrectomy system, called Vitesse PPVX (Bausch + Lomb), offers several advantages over currently available vitrector technology. The device received FDA 510k approval in April 2017.
How adaptive optics will change retinal imaging
How adaptive optics will change retinal imagingAdaptive optics could allow clinicians to monitor the progression of retinal diseases cell-by-cell, according to Jacque Duncan, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further study
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Nystagmus diagnosis begins with thorough eye examA careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
Inhibition of PlGF shows additional features compared to VEGF inhibition
Inhibition of PlGF shows additional features compared to VEGF inhibitionAnti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.